Focus: Bavarian Nordic is a Denmark-based vaccine specialist with 1,001–5,000 employees focused on infectious diseases and immunotherapies. The company operates as a mid-cap biotech with a diversified pipeline spanning approved vaccines, Phase 3 candidates, and early-stage oncology immunotherapies.
Profile data last refreshed 9h ago · AI intelligence enriched 1mo ago
Growing — net +10 jobs in 30d
40 jobs added vs 30 removed. Steady team buildout.
Bavarian Nordic offers meaningful vaccine/immunotherapy exposure and multiple near-term catalysts, but recent guidance misses and opaque financials introduce execution risk for risk-averse candidates.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bavarian Nordic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bavarian Nordic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bavarian Nordic's guidance raise bigger than expected, analyst says - MedWatch
Bavarian Nordic's guidance raise bigger than expected, analyst says MedWatch
What Bavarian Nordic’s next CEO is up against - Pharma Voice
What Bavarian Nordic’s next CEO is up against Pharma Voice
Tarja Stenvall Appointed Chief Executive Officer at Bavarian Nordic - https://hrtoday.in/
Tarja Stenvall Appointed Chief Executive Officer at Bavarian Nordic https://hrtoday.in/
Bavarian Nordic Appoints Tarja Stenvall As CEO To Lead Next Phase Of Global Vaccine Growth - Pulse 2.0
Bavarian Nordic Appoints Tarja Stenvall As CEO To Lead Next Phase Of Global Vaccine Growth Pulse 2.0
Bavarian Nordic Names Former Sanofi Executive as CEO (Correct) - Bloomberg Law News
Bavarian Nordic Names Former Sanofi Executive as CEO (Correct) Bloomberg Law News
Bavarian Nordic turns to Sanofi veteran Tarja Stenvall as chief exec - The Pharma Letter
Bavarian Nordic turns to Sanofi veteran Tarja Stenvall as chief exec The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.
Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo